QSAR and Docking Studies on Piperidyl-cyclohexylurea Derivatives for Prediction of Selective and Potent Inhibitor of Matriptase

Author(s): Agha Zeeshan Mirza*, Hina Shamshad.

Journal Name: Current Computer-Aided Drug Design

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: QSAR models as PLS, GFA, and 3D were developed for a series of matriptase inhibitors using 35 piperidyl-cyclohexylurea compounds. The training and test sets were divided into a set of 28 and 8 compounds, respectively and the pki values of each compound were used in the analysis.

Methods: Docking and alignment methodologies were used to develop models in 3D QSAR. The best models among all were selected on the basis of regression statistics as r2, predictive r2 and Friedman Lack of fit measure. Hydrogen donors and rotatable bonds were found to be positively correlated properties for this target. The models were validated and used for the prediction of new compounds. Based on the predictions of 3D-QSAR model, 17 new compounds were prepared and their activities were predicted and compared with the active compound. Prediction of activities was performed for these 18 compounds using consensus results of all models. ADMET was also performed for the best-chosen compound and compared with the known active.

Results and Conclusion: The developed model was able to validate the obtained results and can be successfully used to predict new potential and active compounds.

Keywords: QSAR, docking studies, piperidyl-cyclohexylurea derivatives, matriptase, ADMET, GFA.

[1]
Zhao, B.; Yuan, C.; Li, R.; Qu, D.; Huang, M.; Ngo, J.C. Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1. J. Biol. Chem., 2013, 288(16), 11155-11164.
[2]
Uhland, K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci., 2006, 63(24), 2968-2978.
[3]
Welman, A.; Sproul, D.; Mullen, P.; Muir, M.; Kinnaird, A.R.; Harrison, D.J.; Faratian, D.; Brunton, V.G.; Frame, M.C. Diversity of matriptase expression level and function in breast cancer. PLoS One, 2012, 7(4), e34182.
[4]
Bergum, C.; Zoratti, G.; Boerner, J.; List, K. Strong expression association between matriptase and its substrate prostasin in breast cancer. J. Cell. Physiol., 2012, 227(4), 1604-1609.
[5]
Oberst, M.D.; Johnson, M.D.; Dickson, R.B.; Lin, C.Y.; Singh, B.; Stewart, M.; Williams, A.; Al-Nafussi, A.; Smyth, J.F.; Gabra, H.; Sellar, G.C. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters expression of the serine protease matriptase and its inhibitor HAI- 1 in epithel. Clin. Cancer Res., 2002, 8(4), 1101-1107.
[6]
Godiksen, S.; Soendergaard, C.; Friis, S.; Jensen, J.K.; Bornholdt, J.; Sales, K.U.; Huang, M.; Bugge, T.H.; Vogel, L.K. Detection of active matriptase using a biotinylated chloromethyl ketone peptide. PLoS One, 2013, 8(10), e77146.
[7]
Friedrich, R.; Fuentes-Prior, P.; Ong, E.; Coombs, G.; Hunter, M.; Oehler, R.; Pierson, D.; Gonzalez, R.; Huber, R.; Bode, W.; Madison, E.L. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem., 2002, 277(3), 2160-2168.
[8]
Quimbar, P.; Malik, U.; Sommerhoff, C.P.; Kaas, Q.; Chan, L.Y.; Huang, Y.H.; Grundhuber, M.; Dunse, K.; Craik, D.J.; Anderson, M.A.; Daly, N.L. High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem., 2013, 288(19), 13885-13896.
[9]
Maya, H.; Eggert, R.; Eva, M.; Andreas, H.; Michael, G.; Gerhard, K.; Torsten, S. New 3-amidinophenylalanine derived inhibitors of matriptase. MedChemComm, 2012, 3, 807-813.
[10]
Munteanu, C.R.; Fernández-Blanco, E.; Seoane, J.A.; Izquierdo-Novo, P.; Rodríguez-Fernández, J.A.; Prieto-González, J.M.; Rabuñal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16(24), 2640-2655.
[11]
Kubinyi, H. QSAR and 3D QSAR in drug design. Part 1: Methodology. Drug Discov. Today, 1997, 2(11), 457-467.
[12]
Pecka, J.; Ponec, R. Simple analytical method for evaluation of statistical importance of correlations in QSAR studies. J. Math. Chem., 2000, 27(1-2), 13-22.
[13]
Carb-Dorca, R.; Besal, E. Extending molecular similarity to energy surfaces: Boltzmann similarity measures and indices. J. Math. Chem., 1996, 20(2), 247-261.
[14]
Quimbar, P.; Malik, U.; Sommerhoff, C.P.; Kaas, Q.; Chan, L.Y.; Huang, Y.H.; Grundhuber, M.; Dunse, K.; Craik, D.J.; Anderson, M.A.; Daly, N.L. High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem., 2013, 288(19), 13885-13896.
[15]
Bkhaitan, M.M.; Mirza, A.Z.; Shamshad, H.; Ali, H.I. Identification of potent virtual leads and ADME prediction of isoxazolidine podophyllotoxin derivatives as topoisomerase II and tubulin inhibitors. J. Mol. Graph. Model., 2017, 73, 74-93.
[16]
RCSB PDB, University of New Jersey, Department of Chemistry and Chemical Biology 610 Taylor Road, (n.d.)..
[17]
Bkhaitan, M.M.; Mirza, A.Z.; Abdalla, A.N.; Shamshad, H.; Ul-Haq, Z.; Alarjah, M.; Piperno, A. Reprofiling of full-length phosphonated carbocyclic 2′-oxa-3′-aza-nucleosides toward antiproliferative agents: Synthesis, antiproliferative activity, and molecular docking study. Chem. Biol. Drug Des., 2017, 90(5), 679-689.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [167 - 181]
Pages: 15
DOI: 10.2174/1573409914666180516162349
Price: $65

Article Metrics

PDF: 40
HTML: 2

Special-new-year-discount